(Q33928647)

30 July 2017

1 reference

title

Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms, and clinical management. (English)

1 reference

30 July 2017

1 reference

Kaye KS

1

1 reference

PubMed ID

10829257

30 July 2017

Fraimow HS

series ordinal

2

1 reference

PubMed ID

10829257

30 July 2017

Abrutyn E

series ordinal

3

1 reference

30 July 2017

1 June 2000

1 reference

Infectious Disease Clinics of North America

30 July 2017

1 reference

30 July 2017

14

1 reference

30 July 2017

2

1 reference

30 July 2017

293-319

1 reference

Dissemination among staphylococci of DNA sequences associated with methicillin resistance

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Genetics and mechanisms of glycopeptide resistance in enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Risk/benefit in the treatment of children with imipenem-cilastatin for meningitis caused by penicillin-resistant pneumococcus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Further occurrence of extended-spectrum beta-lactamase-producing Salmonella enteritidis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Emergence and nosocomial transmission of ampicillin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Emergence of drug-resistant pneumococcal infections in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

High-level penicillin resistance among isolates of enterococci. Implications for treatment of enterococcal infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Drug-resistant Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Occurrence and detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Transfer of antibiotic resistance genes between gram-positive and gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

An Outbreak of Infections Caused by Strains of Staphylococcus aureus Resistant to Methicillin and Aminoglycosides. I. Clinical Studies

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Antibiotic susceptibility and outer membrane proteins of clinical Xanthomonas maltophilia isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

The molecular and clinical epidemiology of enterobacteriaceae-producing extended-spectrum beta-lactamase in a tertiary care hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Increasing resistance of Staphylococcus aureus to ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Inactivation of antibiotics and the dissemination of resistance genes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

A case-control study of an outbreak of infections caused by Klebsiella pneumoniae strains producing CTX-1 (TEM-3) beta-lactamase

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada--1997 results from the SENTRY Antimicrobial Surveillance Program

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Vancomycin-resistant enterococci. Mechanism and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Detection and clinical significance of extended-spectrum beta-lactamases in a tertiary-care medical center

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Acinetobacter species as nosocomial pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Inconsistent bactericidal activity of triple-combination therapy with vancomycin, ampicillin, and gentamicin against vancomycin-resistant, highly ampicillin-resistant Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Magnitude and prevention of nosocomial infections in the intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Kinetics of antimicrobial activity of aztreonam/clavulanic acid (2:1) against Xanthomonas maltophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Antigenic Variation of Penicillin-Binding Proteins from Penicillin-Resistant Clinical Strains of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Pharmacia Biotech & Science prize. 1997 grand prize winner. Life in the balance: cell walls and antibiotic resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Cytosolic intermediates for cell wall biosynthesis and degradation control inducible beta-lactam resistance in gram-negative bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Genetics of extended-spectrum beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Oxacillin-resistant pneumococci sensitive to penicillin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Treatment failure due to extended spectrum beta-lactamase

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Enterococcus faecium strains with vanA-mediated high-level glycopeptide resistance isolated from animal foodstuffs and fecal samples of humans in the community.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Management of antibiotic-resistant pneumococcal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Pneumococcal resistance to antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis. An explanation for resistance to antibiotic synergism

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus with minocycline

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Transferable vancomycin and teicoplanin resistance in Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

The clinical impact of resistance in the management of pneumococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Acquired carbapenemases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

beta-Lactamases in laboratory and clinical resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Hospital-acquired Infection with Vancomycin-resistant Enterococcus faecium Transmitted by Electronic Thermometers

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Resistance issues and treatment implications: pneumococcus, Staphylococcus aureus, and gram-negative rods.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Extended spectrum beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Comparative susceptibility of clinical isolates producing extended spectrum beta-lactamases to ceftibuten: effect of large inocula

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

The most frequent aminoglycoside resistance mechanisms--changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Gentamicin uptake in wild-type and aminoglycoside-resistant small-colony mutants of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Epidemiology of Klebsiella and Hospital-Associated Infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Geographic Distribution of Penicillin-Resistant Clones of Streptococcus pneumoniae: Characterization by Penicillin-Binding Protein Profile, Surface Protein A Typing, and Multilocus Enzyme Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Involvement of multiple genetic determinants in high-level methicillin resistance in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Beta-lactamase-producing enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

The life and times of the Enterococcus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Evidence for clonal spread of a single strain of beta-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

The crisis in antibiotic resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Prevention of drug access to bacterial targets: permeability barriers and active efflux

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Extended-spectrum beta-lactamases in Pseudomonas aeruginosa.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Risk factors for colonization or infection due to methicillin-resistant Staphylococcus aureus in HIV-positive patients: a retrospective case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Novel plasmid-mediated beta-lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy beta-lactams in clinical isolates of Klebsiella pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum β-lactamase (ESBL-KP) in the intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Multicenter evaluation of the antimicrobial activity for six broad-spectrum beta-lactams in Venezuela using the Etest method. The Venezuelan Antimicrobial Resistance Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Spread of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: are beta-lactamase inhibitors of therapeutic value?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Plasmid-mediated resistance to expanded-spectrum cephalosporins among Enterobacter aerogenes strains

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

beta-Lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Diversity of staphylococci exhibiting high-level resistance to mupirocin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

The spread of multiply resistant Streptococcus pneumoniae at a day care center in Ohio

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

beta-Lactamases of gram-negative bacteria: new challenges for new drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Synergistic killing of vancomycin-resistant enterococci of classes A, B, and C by combinations of vancomycin, penicillin, and gentamicin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Suppression of glycopeptide resistance in a highly teicoplanin-resistant mutant of Staphylococcus aureus by transposon inactivation of genes involved in cell wall synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Resistance to cefotaxime and seven other beta-lactams in members of the family Enterobacteriaceae: a 3-year survey in France

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Genetic diversity of penicillin-binding protein 2B and 2X genes from Streptococcus pneumoniae in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Clindamycin for colonization and infection by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Resistance to antibiotics mediated by target alterations

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Antibiotic resistance in Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

van A-Mediated vancomycin-resistant Enterococcus spp. in sewage

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Comparative in-vitro activity of SCH 27899, a novel everninomicin, and vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Evaluation of vancomycin for therapy of adult pneumococcal meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970249-X

7 January 2021

10.1016/S0891-5520(05)70249-X

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10829257